Compounds > bismuth
Page last updated: 2024-08-26

bismuth and Pancreatic Neoplasms

bismuth has been researched along with Pancreatic Neoplasms in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19901 (10.00)18.7374
1990's1 (10.00)18.2507
2000's4 (40.00)29.6817
2010's3 (30.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Hisatomi, H; Iuchi, K; Shirai, S; Tasaki, Y1
Bruchertseifer, F; Flechsig, P; Giesel, FL; Haberkorn, U; Kratochwil, C; Kuder, T; Schwartz, LH; Wulfert, S; Zechmann, CM1
Bruchertseifer, F; Bryan, RA; Dadachova, E; Epstein, AL; Jandl, T; Jiang, Z; Koba, W; Morgenstern, A; Onyedika, C; Strauss, J1
Allen, BJ; Brechbiel, M; Li, Y; Morgenstern, A; Perkins, AC; Qu, CF; Rizvi, SM; Smith, R; Songl, YJ1
Anderson, TL; Brechbiel, MW; de Jong, M; Garmestani, K; Konings, IR; Krenning, BJ; Kusewitt, DF; Kvols, LK; Nayak, TK; Norenberg, JP1
Allen, BJ; Apostolidis, C; Li, Y; Morgenstern, A; Qu, CF; Raja, C; Rizvi, SM; Smith, R; Song, EY1
Anderson, TL; Atcher, RW; Nayak, TK; Norenberg, JP; Prossnitz, ER; Stabin, MG1
Schiller, LR1
Brechbiel, MW; DeGraff, W; Friedman, AM; Gamson, J; Gansow, OA; Hines, JJ; Kurtzman, SH; Mitchell, JB; Russo, A; Sindelar, WF1

Trials

1 trial(s) available for bismuth and Pancreatic Neoplasms

ArticleYear
Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy.
    Experimental oncology, 2013, Volume: 35, Issue:2

    Topics: Bismuth; Contrast Media; Infusions, Intra-Arterial; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Perfusion Imaging; Positron-Emission Tomography; Radioisotopes; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2013

Other Studies

9 other study(ies) available for bismuth and Pancreatic Neoplasms

ArticleYear
Heterocyclic organobismuth(III) compound induces nonapoptotic cell death via lipid peroxidation.
    Anti-cancer drugs, 2020, Volume: 31, Issue:1

    Topics: alpha-Tocopherol; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Bismuth; Caspase Inhibitors; Cell Death; Cell Line, Tumor; Cell Membrane; Colorectal Neoplasms; Dose-Response Relationship, Drug; HeLa Cells; Humans; Isoquinolines; Lipid Peroxidation; Organometallic Compounds; Pancreatic Neoplasms; Reactive Oxygen Species

2020
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA.
    Expert review of anticancer therapy, 2014, Volume: 14, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bismuth; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Radioimmunotherapy; Radioisotopes; Xenograft Model Antitumor Assays

2014
SNM 2012 image of the year.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, Volume: 53, Issue:10

    Topics: Bismuth; Humans; Intestinal Neoplasms; Liver; Neuroendocrine Tumors; Nuclear Medicine; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Societies, Scientific; Stomach Neoplasms; Treatment Failure

2012
In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.
    Cancer biology & therapy, 2005, Volume: 4, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Bismuth; Cell Line, Tumor; Humans; Isothiocyanates; Mice; Mucin-1; Mucins; Pancreatic Neoplasms; Pentetic Acid; Radioimmunotherapy; Xenograft Model Antitumor Assays

2005
213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-01, Volume: 12, Issue:3 Pt 1

    Topics: Animals; Bismuth; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Octreotide; Pancreatic Neoplasms; Radioisotopes; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Time Factors

2006
Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.
    Clinical & experimental metastasis, 2005, Volume: 22, Issue:7

    Topics: Animals; Bismuth; Cell Line, Tumor; Cell Survival; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Microscopy, Confocal; Neoplasm Metastasis; Pancreatic Neoplasms; Plasminogen Activator Inhibitor 2; Radioisotopes; Radiopharmaceuticals; Transplantation, Heterologous; Urokinase-Type Plasminogen Activator

2005
Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nuclear medicine and biology, 2007, Volume: 34, Issue:2

    Topics: Adenocarcinoma; Alpha Particles; Beta Particles; Bismuth; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Radiation; Drug Delivery Systems; Humans; Lutetium; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Somatostatin; Treatment Outcome

2007
Microscopic colitis syndrome: lymphocytic colitis and collagenous colitis.
    Seminars in gastrointestinal disease, 1999, Volume: 10, Issue:4

    Topics: Adult; Bismuth; Chronic Disease; Colitis; Colonoscopy; Diagnosis, Differential; Diarrhea; Female; Humans; Inflammatory Bowel Diseases; Intestinal Mucosa; Organometallic Compounds; Pancreatic Neoplasms; Prognosis; Salicylates; Vipoma

1999
212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy.
    Journal of the National Cancer Institute, 1988, May-18, Volume: 80, Issue:6

    Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antigens, Surface; Bismuth; Cell Survival; Energy Transfer; Humans; Pancreatic Neoplasms; Radioimmunoassay; Radioisotopes; Tumor Cells, Cultured

1988